HUP0103147A2 - GLP1-et tartalmazó gyógyszerkészítmény és alkalmazása funkcionális diszpepszia és/vagy irritábilis colonszindróma kezelésére - Google Patents

GLP1-et tartalmazó gyógyszerkészítmény és alkalmazása funkcionális diszpepszia és/vagy irritábilis colonszindróma kezelésére

Info

Publication number
HUP0103147A2
HUP0103147A2 HU0103147A HUP0103147A HUP0103147A2 HU P0103147 A2 HUP0103147 A2 HU P0103147A2 HU 0103147 A HU0103147 A HU 0103147A HU P0103147 A HUP0103147 A HU P0103147A HU P0103147 A2 HUP0103147 A2 HU P0103147A2
Authority
HU
Hungary
Prior art keywords
bowel syndrome
irritable bowel
functional dyspepsia
derivatives
treatment
Prior art date
Application number
HU0103147A
Other languages
English (en)
Inventor
Suad Efendic
Per Hellström
Original Assignee
Suad Efendic
Per Hellström
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suad Efendic, Per Hellström filed Critical Suad Efendic
Publication of HUP0103147A2 publication Critical patent/HUP0103147A2/hu
Publication of HUP0103147A3 publication Critical patent/HUP0103147A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány glukagonszerű peptid-1 (GLP-1) és származékainak osztálybatartozó, a gasztrointesztinális rendszerben szekréciógátló és simaizom relaxáns hatással rendelkező, gasztrointesztinális peptidhormononok új alkalmazására vonatkozik, funkcionális diszpepszia és azirritábilis colon szindroma kezelésére alkalmas gyógyszerkészítményelőállítására. A találmány egy gyógyszerkészítményre is vonatkozik,amelyik legalább egyet tartalmaz az említett osztályba tartozó GLP-1vegyületek és származékaik közül kombinációban egy vagy több másgasztrointesztinális peptid hormonnal vagy azok származékaival,farmakológiai szempontból elfogadható adalékanyagokkal együtt,valamint egy módszerre funkcionális diszpepszia vagy irritábilis colonszindróma vagy mindkettő kezelésére legalább egy, az említettosztályba tartozó, fent említett hatásokkal és tulajdonságokkalrendelkező GLP-1 vegyület és származékai hatásos mennyiségénekbeadásával. Ó
HU0103147A 1998-06-11 1999-06-08 Pharmaceutical composition comprising glp1 and their use for the treatment of functional dyspepsia and/or irritable bowel syndrome HUP0103147A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802080A SE9802080D0 (sv) 1998-06-11 1998-06-11 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
PCT/SE1999/000997 WO1999064060A1 (en) 1998-06-11 1999-06-08 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein

Publications (2)

Publication Number Publication Date
HUP0103147A2 true HUP0103147A2 (hu) 2002-01-28
HUP0103147A3 HUP0103147A3 (en) 2002-02-28

Family

ID=20411665

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103147A HUP0103147A3 (en) 1998-06-11 1999-06-08 Pharmaceutical composition comprising glp1 and their use for the treatment of functional dyspepsia and/or irritable bowel syndrome

Country Status (19)

Country Link
US (1) US6348447B1 (hu)
EP (2) EP1405642A1 (hu)
JP (2) JP2002517468A (hu)
AT (1) ATE252912T1 (hu)
AU (1) AU738994B2 (hu)
CA (1) CA2321700C (hu)
CZ (1) CZ300873B6 (hu)
DE (1) DE69912434T2 (hu)
DK (1) DK1094834T3 (hu)
ES (1) ES2205845T3 (hu)
HU (1) HUP0103147A3 (hu)
NO (1) NO327738B1 (hu)
NZ (1) NZ506163A (hu)
PL (1) PL198802B1 (hu)
PT (1) PT1094834E (hu)
RU (1) RU2226402C2 (hu)
SE (1) SE9802080D0 (hu)
WO (1) WO1999064060A1 (hu)
ZA (1) ZA200004080B (hu)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1808438E (pt) 1999-06-29 2015-01-14 Mannkind Corp Purificação e estabilização de péptidos e proteínas em agentes farmacêuticos
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1267912A2 (en) 2000-03-14 2003-01-02 Burkhard Göke Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
AU2001263230B2 (en) * 2000-05-19 2005-03-10 Amylin Pharmaceuticals, Llc Treatment of acute coronary syndrome with glp-1
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
BR0307727A (pt) 2002-02-20 2005-01-25 Lilly Co Eli Fomulação
ATE385193T1 (de) 2002-03-20 2008-02-15 Mannkind Corp Inhalationsgerät
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
EP1633774B1 (en) 2003-06-18 2010-02-17 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
CA2575692C (en) 2004-08-20 2014-10-14 Mannkind Corporation Catalysis of diketopiperazine synthesis
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
EP1874339A1 (en) * 2005-04-21 2008-01-09 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
EP1881850B1 (en) 2005-05-13 2010-09-29 Eli Lilly And Company Glp-1 pegylated compounds
MX2008001468A (es) 2005-06-30 2008-04-07 Sod Conseils Rech Applic Composiciones farmaceuticas del peptido similar al glucagon-1.
WO2007027344A2 (en) * 2005-07-29 2007-03-08 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
DK1937219T3 (en) 2005-09-14 2016-02-15 Mannkind Corp A method for drug formulation based on increasing the affinity of the crystalline surfaces of the microparticle of active principles
IN2015DN00888A (hu) 2006-02-22 2015-07-10 Mannkind Corp
RU2445972C2 (ru) * 2006-12-29 2012-03-27 Ипсен Фарма С.А.С. Фармацевтические композиции glp-1
WO2008134425A1 (en) * 2007-04-27 2008-11-06 Cedars-Sinai Medical Center Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
KR20130123470A (ko) * 2007-10-24 2013-11-12 맨카인드 코포레이션 활성제의 전달
EP2954893A1 (en) * 2007-10-24 2015-12-16 MannKind Corporation An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes
KR101933816B1 (ko) 2008-06-13 2019-03-29 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
RU2543157C2 (ru) 2008-06-17 2015-02-27 Глитек,Инк. Гликозилированный пептид glp-1
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8614185B2 (en) 2009-05-04 2013-12-24 Centocor Ortho Biotech Inc. Fusion proteins of alpha-MSH derivatives and Fc
JP5751641B2 (ja) 2009-05-06 2015-07-22 ヤンセン バイオテツク，インコーポレーテツド メラノコルチン受容体結合コンジュゲート
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
CN102574904B (zh) * 2009-07-29 2014-11-26 第一三共株式会社 赋予了经粘膜吸收性的胃动素样肽化合物
US20120264684A1 (en) 2009-10-30 2012-10-18 Yasuhiro Kajihara Glycosylated Form of Antigenic GLP-1 Analogue
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
US9168288B2 (en) * 2010-04-09 2015-10-27 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
SG184988A1 (en) 2010-04-27 2012-11-29 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
CA2803646A1 (en) 2010-07-02 2012-01-05 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
DK2651398T3 (en) 2010-12-16 2018-03-12 Novo Nordisk As Solid compositions comprising a GLP-1 agonist and a salt of N- (8- (2-hydroxybenzyl) amino) caprylic acid
JP6133270B2 (ja) 2011-04-01 2017-05-24 マンカインド コーポレイション 薬剤カートリッジのためのブリスター包装
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
KR20140100947A (ko) 2011-11-03 2014-08-18 질랜드 파마 에이/에스 Ｇｌｐ-1 수용체 효능제 펩타이드 가스트린 접합체들
RS57727B1 (sr) 2012-03-22 2018-12-31 Novo Nordisk As Kompozicije glp-1 peptida i njihovo dobijanje
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
CN111494324B (zh) 2012-03-22 2023-05-16 诺和诺德股份有限公司 包含递送剂的组合物及其制备
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
ES2624294T3 (es) 2012-07-12 2017-07-13 Mannkind Corporation Sistemas de suministro de fármacos en polvo seco
CA2878991C (en) 2012-07-23 2021-12-07 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP2970149B1 (en) 2013-03-15 2019-08-21 MannKind Corporation Microcrystalline diketopiperazine compositions and methods
BR112016000937A8 (pt) 2013-07-18 2021-06-22 Mannkind Corp formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
US9896495B2 (en) 2013-10-17 2018-02-20 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
JP6682432B2 (ja) 2013-11-06 2020-04-15 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
WO2016066744A2 (en) 2014-10-29 2016-05-06 Zealand Pharma A/S Gip agonist compounds and methods
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
JP6731953B2 (ja) 2015-02-11 2020-07-29 ジーエムエーエックス バイオファーム エルエルシー． Ｇｌｐ−１ｒ抗体融合タンパク質の安定な医薬溶液製剤
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
MX2019006486A (es) 2016-12-09 2019-08-01 Zealand Pharma As Agonistas duales acilados de glp-1/glp-2.
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
CN117126279A (zh) 2018-03-20 2023-11-28 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN112521501A (zh) 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
US5994500A (en) * 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides

Also Published As

Publication number Publication date
CA2321700A1 (en) 1999-12-16
CZ20004491A3 (en) 2001-05-16
JP2010270125A (ja) 2010-12-02
ES2205845T3 (es) 2004-05-01
ZA200004080B (en) 2001-12-24
AU738994B2 (en) 2001-10-04
EP1405642A1 (en) 2004-04-07
JP2002517468A (ja) 2002-06-18
HUP0103147A3 (en) 2002-02-28
DE69912434D1 (de) 2003-12-04
ATE252912T1 (de) 2003-11-15
US6348447B1 (en) 2002-02-19
PL198802B1 (pl) 2008-07-31
PL343104A1 (en) 2001-07-30
RU2226402C2 (ru) 2004-04-10
NZ506163A (en) 2004-10-29
NO20006194D0 (no) 2000-12-06
DE69912434T2 (de) 2004-05-06
NO327738B1 (no) 2009-09-14
WO1999064060A1 (en) 1999-12-16
DK1094834T3 (da) 2004-01-05
CA2321700C (en) 2011-05-03
PT1094834E (pt) 2004-03-31
SE9802080D0 (sv) 1998-06-11
EP1094834A1 (en) 2001-05-02
NO20006194L (no) 2001-01-25
CZ300873B6 (cs) 2009-09-02
EP1094834B1 (en) 2003-10-29
AU4669799A (en) 1999-12-30

Similar Documents

Publication Publication Date Title
HUP0103147A2 (hu) GLP1-et tartalmazó gyógyszerkészítmény és alkalmazása funkcionális diszpepszia és/vagy irritábilis colonszindróma kezelésére
TR200100377T2 (tr) Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar.
ATE394423T1 (de) Analoge des glucagon ähnlichen peptides-1 (glp-1)
HUP0301194A2 (hu) Dipeptidil-peptidáz IV. inhibitorokból és más antidiabetikus szerekből álló kombinációs készítmények és alkalmazásuk diabetes mellitus kezelésére
SG125915A1 (en) Analogues of glp-1
RU2000133249A (ru) Фармацевтическая композиция для лечения функциональной диспепсии и/или синдрома раздраженной толстой кишки и новое применение веществ в ней
ATE522226T1 (de) Verfahren und zusammensetzungen zur behandlung des polyzystischen ovarialsyndroms
BR0212080A (pt) composto de glp-1, método de estimulação de receptor de glp-1 em um indivìduo necessitando de tal estimulação, e, uso de um composto de glp-1
AR034132A1 (es) Analogos de somatostatina, un proceso para su produccion y composicion farmaceutica
RS49756B (sr) Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija
DE60023492D1 (de) Glucagon antagonisten/inverse agonisten
BR9509019A (pt) Processo para fabricar unidades de dosagem farmacêutica e comprimido isento de solventes orgânicos
DK0736039T3 (da) Forbindelser med væksthormon-frigivende egenskaber
AU2610799A (en) Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
DE60110054D1 (en) Cardioprotektive phosphonate
MY116002A (en) Nk-1 receptor antagonists and 5ht3 receptor antagonists for the treatment of emesis
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
BRPI0417948A (pt) derivados de quinuclidina substituìda por bicicloheterociclo fundido
NO20080552L (no) GLP-1 farmasoytiske sammensetninger
ES2122015T3 (es) Uso de urodilatina en enfermedades pulmonares y bronquiales.
AR035730A1 (es) Derivados de 2-arilamino-2,3-dihidrotiazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento
HUP9701016A2 (hu) Teofillinszármazékok alkalmazása sokkos állapotok kezelésére használható gyógyszerkészítmények előállítására, új xantinvegyületek, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
ES2188909T3 (es) Nuevos derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes o enfermedades relacionados con el estrogeno. os
EP1359159A3 (en) Analogues of GLP-1

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees